Research on cellular signal transduction is highly relevant for the development of new cancer therapies. Related research activities are ongoing within the Jena University Hospital (JUH) but also at the Institute of Biochemistry and Biophysics of the Faculty of Biology and Pharmacy (IBB), and the Leibniz Institute for Age Research, Fritz-Lipmann Institute (FLI). There is a history of collaboration between a number of these research groups often in basic research in the framework of the DFG SFB 604 “Multifunctional Signaling Proteins” (2002-2009). Further interactions, notably between basic research and clinic, shall be fostered in the corresponding section of the CCC by implementing the specific CCC activities of education and training and by providing access to the infrastructural funds.
Hughes T, Saglio G, Branford S, Soverini S, Kim DW, Müller MC, Martinelli G, Cortes J, Beppu L, Gottardi E, Kim D, Erben P, Shou Y, Haque A, Gallagher N, Radich J, Hochhaus A. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol. 2009, 27:4204-10.
Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, Jones AV, Waghorn K, Zoi K, Ross FM, Reiter A, Hochhaus A, Drexler HG, Duncombe A, Cervantes F, Oscier D, Boultwood J, Grand FH, Cross NC. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet. 2010, 42:722-6.